BioCryst Pharma (BCRX) Tops Q3 EPS by 11c ; Offers Guidance
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.70 --0%
Revenue Growth %: +3.9%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
VFS, More
Revenue Growth %: +3.9%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
VFS, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q3 EPS of $0.16, $0.11 better than the analyst estimate of $0.05. Revenue for the quarter came in at $159.1 million versus the consensus estimate of $162.97 million.
GUIDANCE:
BioCryst Pharma sees FY2025 revenue of $590-600 million, versus the consensus of $626.1 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Downgrades Fluence Energy Inc. (FLNC) to Hold
- BMO Capital Downgrades Linamar Corp (LNR:CN) (LIMAF) to Market Perform
- salesforce.com (CRM) Reiterated at Market Outperform by Citizens on Broad Platform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
